244 related articles for article (PubMed ID: 23287859)
1. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.
Zhang Q; Hossain DM; Nechaev S; Kozlowska A; Zhang W; Liu Y; Kowolik CM; Swiderski P; Rossi JJ; Forman S; Pal S; Bhatia R; Raubitschek A; Yu H; Kortylewski M
Blood; 2013 Feb; 121(8):1304-15. PubMed ID: 23287859
[TBL] [Abstract][Full Text] [Related]
2. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.
Hossain DM; Dos Santos C; Zhang Q; Kozlowska A; Liu H; Gao C; Moreira D; Swiderski P; Jozwiak A; Kline J; Forman S; Bhatia R; Kuo YH; Kortylewski M
Blood; 2014 Jan; 123(1):15-25. PubMed ID: 24169824
[TBL] [Abstract][Full Text] [Related]
3. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.
Zhang Q; Hossain DM; Duttagupta P; Moreira D; Zhao X; Won H; Buettner R; Nechaev S; Majka M; Zhang B; Cai Q; Swiderski P; Kuo YH; Forman S; Marcucci G; Kortylewski M
Blood; 2016 Mar; 127(13):1687-700. PubMed ID: 26796361
[TBL] [Abstract][Full Text] [Related]
4. Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape.
Nechaev S; Gao C; Moreira D; Swiderski P; Jozwiak A; Kowolik CM; Zhou J; Armstrong B; Raubitschek A; Rossi JJ; Kortylewski M
J Control Release; 2013 Sep; 170(3):307-15. PubMed ID: 23777886
[TBL] [Abstract][Full Text] [Related]
5. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.
Kortylewski M; Moreira D
Cancer Immunol Immunother; 2017 Aug; 66(8):979-988. PubMed ID: 28214929
[TBL] [Abstract][Full Text] [Related]
6. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.
Kortylewski M; Swiderski P; Herrmann A; Wang L; Kowolik C; Kujawski M; Lee H; Scuto A; Liu Y; Yang C; Deng J; Soifer HS; Raubitschek A; Forman S; Rossi JJ; Pardoll DM; Jove R; Yu H
Nat Biotechnol; 2009 Oct; 27(10):925-32. PubMed ID: 19749770
[TBL] [Abstract][Full Text] [Related]
7. TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells.
Moreira D; Zhang Q; Hossain DM; Nechaev S; Li H; Kowolik CM; D'Apuzzo M; Forman S; Jones J; Pal SK; Kortylewski M
Oncotarget; 2015 Jul; 6(19):17302-13. PubMed ID: 26046794
[TBL] [Abstract][Full Text] [Related]
8. TLR9-Targeted SiRNA Delivery In Vivo.
Hossain DM; Moreira D; Zhang Q; Nechaev S; Swiderski P; Kortylewski M
Methods Mol Biol; 2016; 1364():183-96. PubMed ID: 26472451
[TBL] [Abstract][Full Text] [Related]
9. STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers.
Moreira D; Adamus T; Zhao X; Su YL; Zhang Z; White SV; Swiderski P; Lu X; DePinho RA; Pal SK; Kortylewski M
Clin Cancer Res; 2018 Dec; 24(23):5948-5962. PubMed ID: 30337279
[TBL] [Abstract][Full Text] [Related]
10. TLR9 is critical for glioma stem cell maintenance and targeting.
Herrmann A; Cherryholmes G; Schroeder A; Phallen J; Alizadeh D; Xin H; Wang T; Lee H; Lahtz C; Swiderski P; Armstrong B; Kowolik C; Gallia GL; Lim M; Brown C; Badie B; Forman S; Kortylewski M; Jove R; Yu H
Cancer Res; 2014 Sep; 74(18):5218-28. PubMed ID: 25047528
[TBL] [Abstract][Full Text] [Related]
11. B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.
Zhao X; Zhang Z; Moreira D; Su YL; Won H; Adamus T; Dong Z; Liang Y; Yin HH; Swiderski P; Pillai RK; Kwak L; Forman S; Kortylewski M
Mol Ther; 2018 Mar; 26(3):695-707. PubMed ID: 29433938
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma.
Brignole C; Marimpietri D; Di Paolo D; Perri P; Morandi F; Pastorino F; Zorzoli A; Pagnan G; Loi M; Caffa I; Erminio G; Haupt R; Gambini C; Pistoia V; Ponzoni M
Cancer Res; 2010 Dec; 70(23):9816-26. PubMed ID: 20935225
[TBL] [Abstract][Full Text] [Related]
13. Targeted nanoparticle delivery overcomes off-target immunostimulatory effects of oligonucleotides and improves therapeutic efficacy in chronic lymphocytic leukemia.
Yu B; Mao Y; Bai LY; Herman SE; Wang X; Ramanunni A; Jin Y; Mo X; Cheney C; Chan KK; Jarjoura D; Marcucci G; Lee RJ; Byrd JC; Lee LJ; Muthusamy N
Blood; 2013 Jan; 121(1):136-47. PubMed ID: 23165478
[TBL] [Abstract][Full Text] [Related]
14. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of TLR9 expression affects the maturation and function of murine bone marrow-derived dendritic cells induced by CpG.
Ma L; Zhao G; Hua C; Li X; Zhao X; Sun L; Hou Y
Cell Mol Immunol; 2009 Jun; 6(3):199-205. PubMed ID: 19567203
[TBL] [Abstract][Full Text] [Related]
16. TLR9 signaling promotes tumor progression of human lung cancer cell in vivo.
Ren T; Xu L; Jiao S; Wang Y; Cai Y; Liang Y; Zhou Y; Zhou H; Wen Z
Pathol Oncol Res; 2009 Dec; 15(4):623-30. PubMed ID: 19319670
[TBL] [Abstract][Full Text] [Related]
17. Targeted silencing of genes related to acute monocytic leukaemia by CpG(B)-MLAA-34 siRNA conjugates.
Huang B; He A; Zhang P; Ma X; Yang Y; Wang J; Wang J; Zhang W
J Drug Target; 2020 Jun; 28(5):516-524. PubMed ID: 31718329
[TBL] [Abstract][Full Text] [Related]
18. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells.
Liang X; Moseman EA; Farrar MA; Bachanova V; Weisdorf DJ; Blazar BR; Chen W
Blood; 2010 Jun; 115(24):5041-52. PubMed ID: 20339095
[TBL] [Abstract][Full Text] [Related]
19. CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion.
Sanjuan MA; Rao N; Lai KT; Gu Y; Sun S; Fuchs A; Fung-Leung WP; Colonna M; Karlsson L
J Cell Biol; 2006 Mar; 172(7):1057-68. PubMed ID: 16567503
[TBL] [Abstract][Full Text] [Related]
20. BAX as the mediator of C-MYC sensitizes acute lymphoblastic leukemia to TLR9 agonists.
Bai L; Zhou L; Han W; Chen J; Gu X; Hu Z; Yang Y; Li W; Zhang X; Niu C; Chen Y; Li H; Cui J
J Transl Med; 2023 Feb; 21(1):108. PubMed ID: 36765389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
